Cantargia presents new preclinical data on CAN04 at the 2020 AACR Annual Meeting
· Both parts of the IL-1 system are upregulated in tumor tissue after chemotherapy · CAN04, blocking the activity of both forms of IL-1, increases the efficacy of several different chemotherapy regimes Cantargia AB (“Cantargia”) today presented new preclinical data giving additional knowledge around the mechanisms and thereby relevance of adding the clinical stage antibody CAN04 to chemotherapy. CAN04 combined with different chemotherapy regimens resulted in additive or synergistic antitumor effects and the results were presented at the 2020 Annual Meeting of the American Association